Home -> Law Blog Directory -> Patent Law Blogs -> Patently Obvious
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Patent Law
: Patently ObviousFederal Circuit Finds Stent Patent Obvious by Combining Embodiments in a Single Prior Art Reference
By Dennis Crouch, Esq.
Boston Scientific v. Cordis (Fed. Cir. 2009)
In 2003, Boston Scientific sued Cordis for infringement of its drug-eluting, non-thrombogenic, expandable stent. (Patent No. 6,120,536). The stent, thus has a metal core surrounded by a drugged layer that is then surrounded by a non-thrombogenic layer. A jury found the asserted claims infringed and not obvious. The district court accepted the jury verdict and denied the Cordis motions for JMOL and a new trial. On appeal, the Federal Circuit reversed ? finding the patent obvious as a matter of law.
Cordis pointed to another Medtronic patent ("Wolff") as prior art that ? by itself ? renders the claims invalid. Wolff discloses two separate embodiments: (Fig 4) a metallic core with a drug-eluting coating and (Fig 3B) a drug-eluting core with a non-thombogenic coating. Thus, Wolff "teaches all of the [claimed] limitations. . . . The only qualification to this statement of fact is that all of the limitations are found in two separate embodiments pictured side by side in the patent, not in one embodiment."
Applying KSR, the Federal Circuit found that it would have been obvious to combine the two embodiments since the combination was simply a "predictable variation."
"Combining two embodiments disclosed adjacent to each other in a prior art patent does not require a leap of inventiveness." |
Holding: The asserted claim "would have been obvious in view of Wolff."
Note: The Cordis brief used a particularly effective strategy of including the two embodiments to be combined followed by a demonstrative drawing of how they would have been combined. Here, they used the same drawing style and also used the same figure numbering.
Full post as published by Patently Obvious on January 16, 2009 (boomark / email).
Privacy Protection Act 42 USC 21A
Federal Newsroom Law
Federal Adoption Tax Credit
Financial Incentive for Adoptive Parents
Transportation Equity Act for the 21st Century
TEA-21 - Plus Law 105-178
Bunn-O-Matic
Recalls Single Cup Tea/Coffeemakers
Specialty Lamp International
Recalls Counterfeit Circuit Breakers
Bank Website Security
New Report Finds Widespread Flaws
Zantac Patent
GlaxoSmithKline and Cypress Pharmaceutical settle patent infringement dispute.
Soliris Patent
Alexion Pharmaceuticals Inc. agrees to pay the Oklahoma Medical Research Foundation a $10 million patent infringement settlement.
DRAM Patent
ProMOS Technologies and Mosel Vitelic pay MOSAID Technologies an undisclosed patent infringement settlement.

Assessing patent validity: Prior art can anticipate patent claim even if claim is non-obvious
Jury's pre-KSR nonobviousness verdict reversed post-KSR
General disclosure in prior art not enabling for specific pharmaceutical compound's use in treatment
Another day in the stent patent wars
Prior court decision of no invalidity based on prior art reference doesn't bar reexamination
In re Kubin to Be Argued before the Federal Circuit on Thursday








